Table 3.
Association between DNA repair polymorphisms and platinum-based chemotherapy prognosis.
| PFS/OS | Gene | Polymorphism | Genotype | MST (year) | Additive | Dominant | Recessive | |||
|---|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P | |||||
| PFS | RPA1 | rs5030740 | CC | 3.72 | 0.67 (0.40-1.13) | 0.136 | 0.76 (0.43-1.34) | 0.341 | 0.08 (0.01-0.83) | 0.034 |
| CT | 3.28 | |||||||||
| TT | 3.07 | |||||||||
| OS | EXO1 | rs1776148 | AA | 6.96 | 0.44 (0.25-0.77) | 0.004 | 0.48 (0.23-0.99) | 0.048 | ||
| AG | 4.34 | |||||||||
| GG | 4.20 | |||||||||
| EXO1 | rs1047840 | AA | 5.43 | 0.67 (0.37-1.20) | 0.177 | 0.80 (0.39-1.66) | 0.551 | 0.24 (0.07-0.82) | 0.023 | |
| AG | 4.66 | |||||||||
| GG | 3.89 | |||||||||
MST: median survival time. Additive model: comparison between minor allele subjects and major allele subjects. Dominant model: comparison between minor allele carriers and major homozygous subjects. Recessive model: comparison between major allele carriers and minor homozygous subjects. ∗P < 0.05.